| Withdrawn | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive S NCT05161533 | University of Washington | Phase 2 |
| Unknown | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer NCT05498389 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer NCT05340309 | University of Southern California | Phase 2 |
| Recruiting | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT05234307 | Dwight Owen | Phase 1 |
| Recruiting | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer NCT05493566 | Emory University | EARLY_Phase 1 |
| Terminated | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue NCT05407038 | Mayo Clinic | N/A |
| Withdrawn | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer NCT05364645 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small C NCT05334329 | University of California, Irvine | Phase 1 |
| Completed | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial NCT05339022 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Can NCT05215769 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual NCT05096663 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Active Not Recruiting | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer NCT05166616 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic NCT05017025 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung NCT04919382 | Dwight Owen | Phase 2 |
| Recruiting | Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lu NCT04780568 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lu NCT04919369 | Dwight Owen | Phase 1 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Canc NCT04971187 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer NCT05045404 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer NCT05342571 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity NCT04954885 | Ohio State University Comprehensive Cancer Center | — |
| Active Not Recruiting | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lun NCT04625647 | SWOG Cancer Research Network | Phase 2 |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metasta NCT04785287 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Pos NCT04837716 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Nurse-Led Intervention for Fear of Progression in Advanced Cancer NCT04819997 | City of Hope Medical Center | N/A |
| Recruiting | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer NCT04762199 | Emory University | Phase 1 |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Pro NCT05022394 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Recruiting | Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-s NCT04751747 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth F NCT04285671 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-S NCT04728230 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 7 NCT04533451 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Active Not Recruiting | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-s NCT04250545 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer NCT04396535 | Mayo Clinic | Phase 2 |
| Withdrawn | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous C NCT04267913 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis NCT04516070 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Family Caregivers in Underserved Populations Providing Complex Cancer Care NCT05213078 | City of Hope Medical Center | N/A |
| Completed | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Muta NCT04479306 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Can NCT04120454 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1 NCT04340882 | Emory University | Phase 2 |
| Active Not Recruiting | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-s NCT03965689 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) NCT04268550 | SWOG Cancer Research Network | Phase 2 |
| Withdrawn | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer NCT04262869 | Emory University | Phase 2 |
| Active Not Recruiting | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCL NCT04227028 | City of Hope Medical Center | Phase 1 |
| Completed | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung C NCT04173507 | SWOG Cancer Research Network | Phase 2 |
| Completed | Resiliency Among Older Adults Receiving Lung Cancer Treatment NCT04229381 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lun NCT04073745 | Roswell Park Cancer Institute | Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Withdrawn | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing P NCT04186988 | University of California, Davis | EARLY_Phase 1 |
| Active Not Recruiting | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study NCT04430725 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell NCT03737994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell NCT03546361 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer NCT03995667 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-smal NCT03971474 | SWOG Cancer Research Network | Phase 2 |
| Completed | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NCT03845296 | SWOG Cancer Research Network | Phase 2 |
| Completed | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell L NCT03581487 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or NCT03902535 | City of Hope Medical Center | — |
| Active Not Recruiting | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage S NCT03830918 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer NCT03944265 | Thomas Jefferson University | N/A |
| Recruiting | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non NCT03948100 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung NCT03707938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancie NCT04662645 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer NCT03637816 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small NCT03731585 | M.D. Anderson Cancer Center | N/A |
| Terminated | Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer NCT03662074 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Bronchoscopic Laser Ablation of Peripheral Lung Tumors NCT03707925 | M.D. Anderson Cancer Center | N/A |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Recruiting | Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery NCT03582124 | Stanford University | Phase 1 / Phase 2 |
| Active Not Recruiting | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic NCT03225664 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Can NCT03410043 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment NCT02589522 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or NCT02955290 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | 4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis NCT00862680 | M.D. Anderson Cancer Center | — |